Status of renal replacement therapy and peritoneal dialysis in Mexico.
Mexico is struggling to gain a place among developed countries; however, there are many socioeconomic and health problems still waiting for resolution. While Mexico has the twelfth largest economy in the world, a large portion of its population is impoverished. Treatment for end-stage renal disease (377 patients per million population) is determined by the individual's access to resources such as private medical care (approximately 3%) and public sources (Social Security System: approximately 40%; Health Secretariat: approximately 57%). With only 6% of the gross national product spent on healthcare and most treatment providers being public health institutions that are often under economic restrictions, it is not surprising that many Mexican patients do not receive renal replacement therapy. Mexico is still the country with the largest utilization of peritoneal dialysis (PD) in the world, with 18% on automated PD, 56% on continuous ambulatory PD (CAPD), and 26% on hemodialysis. Results of PD (patient morbi-mortality, peritonitis rate, and technique survival) in Mexico are comparable to other countries. However, malnutrition and diabetes mellitus are highly prevalent in Mexican patients on CAPD programs, and these conditions are among the most important risk factors for a poor outcome in our setting.
Cueto-Manzano
Alfonso M
AM
Unidad de Investigación Médica en Epidemiología Clínica, UMAE, Hospital de Especialidades, CMNO, IMSS, Guadalajara, Mexico. a_cueto_manzano@hotmail.com
Rojas-Campos
Enrique
E
D003695:Delivery of Health Care / Q000458:organization & administration; D006801:Humans; D019458:Insurance Coverage; D007348:Insurance, Health; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000628:therapy*; D008800:Mexico / Q000453:epidemiology; D017582:Renal Replacement Therapy / Q000191:economics / Q000706:statistics & numerical data*; D016896:Treatment Outcome